This website uses cookies

Read our Privacy policy and Terms of use for more information.

Good morning! Welcome to another edition of Pressure Support, a weekly newsletter simplifying pulmonary and critical care medicine—and the systems that shape it.

Spending my weekend on call working the consult service. Talk about sink or swim… I’m treading water.

If you have colleagues who’d benefit from this newsletter, share it with them using the link below:

I’m alpha testing this newsletter—so please let me know your feedback.

SOAR Act: How Medicare Could Improve Home Oxygen Access

Read the full article here.

This pragmatic cohort study of 367 lung transplant recipients enrolled in a 36-session outpatient pulmonary rehabilitation program found that 78% completed discharge testing and improved their 6-minute walk distance by a median 171 meters (61%); greater baseline function predicted smaller gains, while female sex, higher BMI, and longer hospital stay were also associated with less improvement, and pre-transplant disease severity was not. I think the key takeaway is that standard Medicare-style rehab delivers meaningful, fairly consistent functional recovery after transplant, so the workflow opportunity is making sure patients are enrolled and supported through completion rather than overcomplicating the protocol.

In two 52-week randomized trials, oral orforglipron significantly lowered the apnea-hypopnea index in adults with obesity and moderate-to-severe OSA, whether or not they were using positive airway pressure, with placebo-adjusted reductions of 13.2 and 12.0 events per hour and about 10% weight loss; gastrointestinal side effects were common. The results are pretty compelling for an oral, weight-directed option that could reduce some of the setup and adherence friction around PAP, but I’d still want longer-term outcomes and real-world adherence data before this changes practice.

The 2027 GOLD update argues that COPD is diagnosed too late and should no longer be framed as a smoking-related disease affecting only older men; it broadens the risk factors, emphasizes earlier and more personalized diagnosis, puts pulmonary rehab and other non-drug care up front, and shifts initial group A therapy to a LAMA while adding guidance on early, mild, and young-onset COPD and mucus plugging. My take is that the biggest practical opportunity is process-oriented—earlier case-finding and reliable rehab referral may matter more than another incremental medication change—though LAMA cost and limited evidence in younger patients are real implementation gaps.

An international multicenter observational study of 28,795 ICU patients found that each one-patient increase in the pharmacist-to-patient ratio was associated with a 1% increase in the odds of in-hospital mortality, while missing pharmacist-delivered comprehensive medication management on even one ICU day was associated with 20% higher odds; ratios of 1:15.1–1:46 were also linked to 10% higher mortality odds than 1:7–1:15. This strengthens the case for treating daily ICU pharmacist coverage and manageable workloads as core patient-safety infrastructure, although the observational design means staffing and mortality relationships could still be confounded.

The article uses the Rahn diagram to show how lung and chest-wall compliance shape plateau pressure, transpulmonary pressure, and right-ventricular preload and afterload during mechanical ventilation, which helps explain why pulse-pressure variation can mislead us about fluid responsiveness. This is a really useful physiology refresher because it pushes us to interpret ventilator pressures in context and choose more reliable bedside tests—like passive leg raise or end-expiratory occlusion—when respiratory mechanics are abnormal.

This CHEST study used Optum claims data from 2018–2022 and found that U.S. bronchiectasis prevalence was 221.6 per 100,000 people, rising with age and higher among women, Asian patients, and Medicare Advantage enrollees; pediatric prevalence was 11.9 per 100,000, and most cases were non-CF-related. The rising burden supports earlier recognition and more streamlined, equitable bronchiectasis pathways, although the claims-based design and industry funding mean we should be thoughtful about how directly these estimates translate into clinical planning.

CRITICAL CARE
A fast-flush test produces a square wave followed by only one small oscillation before the tracing returns to baseline. How should this result be interpreted?

Let me know your feedback!

Keeping it simple,

Jared